MIRA
MIRA PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.76
+3.27%Sep 1, 2026, 12:00 UTC
MIRA Pharmaceuticals announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs, advancing the non-opioid oral drug toward an IND filing.
Source:Aug 6, 2026, 12:00 UTC
MIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of its obesity treatment candidate SKNY-1 in Beagle dogs, supporting advancement toward GLP toxicology studies and IND-enabling development.
Source:Jul 10, 2026, 12:00 UTC
MIRA Pharmaceuticals announced positive preclinical results for an optimized oral formulation of MIRA-55, a non-opioid therapy for chronic inflammatory pain.
Source:Jul 6, 2026, 13:00 UTC
MIRA Pharmaceuticals announced positive preclinical results for the oral formulation of its drug candidate SKNY-1 for obesity and addiction.
Source:Jun 4, 2026, 00:00 UTC
MIRA Pharmaceuticals entered into an amended and restated exclusive license agreement with Miralogx LLC, granting MIRA worldwide exclusive rights to intellectual property related to the MIRA-55 and SKNY-1 development programs.
Source: